EZH2 and esophageal cancer: Our results demonstrate that by repressing the expression of EZH2 in esophageal cancer cells, the EMT pathway and as a result, cell migration and metastasis are reduced, which can increase the hopefulness of esophageal cancer patients for treatment without recurrence and increase the survival rate in patients.